The purpose of the study is to evaluate the efficacy (how well the medicines work) and
tolerability (whether participants stop treatment because of side effects from a drug or
treatment) of an anti-TB treatment regimen that compares two doses of linezolid (LZD),
combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ). This study will also
measure the level of these medicines in the participants' blood.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)